Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Arbutus Biopharma's Business Segments
Arbutus Biopharma's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 179
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 179 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- License99.8%
- Collaboration and Contracts0.1%
- Non-Cash Royalty0.1%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 179 | 99.8% |
| Collaboration and Contracts | $ 0 | 0.1% |
| Non-Cash Royalty | $ 0 | 0.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Arbutus Biopharma
Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is a biotechnology company headquartered in Warminster, Pennsylvania, United States. The company has a focus on developing novel therapeutics that address hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), and other liver diseases.
Their lead product candidate, AB-729, is a potentially first-in-class RNA interference (RNAi) therapeutic targeting HBV surface antigen, with the aim of achieving sustained virologic responses in patients. The drug utilizes Arbutus' proprietary GalNAc delivery technology, which is designed to specifically deliver RNAi agents to hepatocytes, the primary liver cells responsible for HBV replication.
Arbutus Biopharma operates a fully integrated research and development center in Burnaby, British Columbia, Canada, which includes chemistry and bioanalytical laboratories, as well as manufacturing facilities for clinical and commercial production of its drug products. The company has a strong intellectual property portfolio consisting of a variety of patents and patent applications that cover its drug candidates, delivery technologies and manufacturing processes.
The company has collaborations with a number of other biotech and pharmaceutical companies, including Roivant Sciences and Gritstone Oncology, aimed at developing RNAi therapies for the treatment of a variety of diseases. Arbutus also collaborates with the Baruch S Blumberg Institute, a renowned research institute based in Doylestown, Pennsylvania, to discover and develop new drug candidates for the treatment of liver diseases.
Arbutus Biopharma was founded in 2005 and went public in 201 The company is traded on the NASDAQ Global Market under the ticker symbol "ABUS".
Their lead product candidate, AB-729, is a potentially first-in-class RNA interference (RNAi) therapeutic targeting HBV surface antigen, with the aim of achieving sustained virologic responses in patients. The drug utilizes Arbutus' proprietary GalNAc delivery technology, which is designed to specifically deliver RNAi agents to hepatocytes, the primary liver cells responsible for HBV replication.
Arbutus Biopharma operates a fully integrated research and development center in Burnaby, British Columbia, Canada, which includes chemistry and bioanalytical laboratories, as well as manufacturing facilities for clinical and commercial production of its drug products. The company has a strong intellectual property portfolio consisting of a variety of patents and patent applications that cover its drug candidates, delivery technologies and manufacturing processes.
The company has collaborations with a number of other biotech and pharmaceutical companies, including Roivant Sciences and Gritstone Oncology, aimed at developing RNAi therapies for the treatment of a variety of diseases. Arbutus also collaborates with the Baruch S Blumberg Institute, a renowned research institute based in Doylestown, Pennsylvania, to discover and develop new drug candidates for the treatment of liver diseases.
Arbutus Biopharma was founded in 2005 and went public in 201 The company is traded on the NASDAQ Global Market under the ticker symbol "ABUS".
Arbutus Biopharma Corp is a biotech firm fundamentally dedicated to the discovery, development, and commercialization of innovative therapies aimed at curing infectious diseases, with a distinctive focus on leveraging RNA technologies. The company’s extensive offerings can be classified into several segments, each encompassing various products and services that advance its overarching mission.
Segments
1. Research and Development Segment:
- Arbutus Biopharma Corp invests significantly in research and development (R&D) activities, engaging a highly skilled team of scientists, researchers, and medical professionals. The R&D segment is at the heart of the company’s innovation strategy and involves collaborative efforts to explore new therapeutic targets and develop transformative RNA-based therapies.
- This segment is dedicated to identifying novel mechanisms of action and innovative technological advancements that improve the efficacy and safety of potential therapies. The focus is on understanding viral pathogenesis, host-virus interactions, and immune responses to better tailor therapies that can effectively combat infections.
2. Therapeutics Segment:
- The therapeutics segment is characterized by a portfolio of RNA-based therapies that target a range of viral infections, including but not limited to hepatitis B, HIV, and influenza. These therapies are in various stages of clinical development, demonstrating the companys commitment to bringing effective treatments to market for significant public health challenges.
- In addition to these viral indications, Arbutus explores potential applications of its RNA-based therapies in oncology and other viral infections, showcasing the versatility and potential of RNA technology to address multiple diseases.
- Preclinical studies are actively conducted to evaluate the safety and efficacy of these therapies, contributing to the robust pipeline of drug candidates in development.
3. Partnerships Segment:
- Arbutus Biopharma strategically engages in partnerships and collaborations with leading pharmaceutical companies, biotechnology firms, and academic institutions globally. These alliances are intended to expedite the development and commercialization of RNA-based therapies.
- The company actively licenses proprietary technologies and intellectual property rights to foster innovation and leverage external expertise, enhancing its capability to bring novel therapies to patients.
- Collaborative efforts often include sharing resources and knowledge, which can lead to synergistic advancements in RNA technology and therapeutic applications.
Products and Services
1. Lipid Nanoparticle (LNP) Technology:
- Arbutus holds a comprehensive patent portfolio related to LNP technology, which serves as a crucial delivery system for RNA-based therapies. Their proprietary LNP platform facilitates the efficient and targeted delivery of therapeutic RNA molecules to specific organs and tissues.
- This technology has gained prominence in the sector and has been employed in various approved RNA-based treatments for conditions such as cancer and rare diseases, highlighting its effectiveness in enhancing therapeutic outcomes.
2. C-Mer Side Effect Mitigation Technology:
- The C-Mer technology developed by Arbutus is designed to significantly reduce the side effects associated with RNA-based therapies. By mitigating the activation of the innate immune system, which can lead to potentially toxic responses, this proprietary technology enhances the safety profile of these therapies.
- This innovation is crucial, as reducing adverse effects can improve patient adherence and overall treatment efficacy, making it a vital component of the companys therapeutic offerings.
3. HBV RNAi Portfolio:
- The HBV RNAi portfolio encompasses a suite of RNA interference (RNAi)-based therapies specifically targeting the hepatitis B virus. These therapeutic candidates have shown promise through multiple preclinical trials, and many are currently advancing into clinical evaluation phases.
- The versatility of RNAi technology for silencing viral genes presents a novel approach to treating chronic hepatitis B, and this portfolio exemplifies Arbutuss commitment to addressing significant unmet medical needs in virology.
Overall, Arbutus Biopharma Corp operates at the cutting edge of scientific innovation, focusing on RNA-based therapeutic solutions to address infectious diseases. With a strong emphasis on R&D, a diverse pipeline of therapeutic candidates, and strategic partnerships, the company remains committed to enhancing patient outcomes through the development and commercialization of its technologies and therapies.
Segments
1. Research and Development Segment:
- Arbutus Biopharma Corp invests significantly in research and development (R&D) activities, engaging a highly skilled team of scientists, researchers, and medical professionals. The R&D segment is at the heart of the company’s innovation strategy and involves collaborative efforts to explore new therapeutic targets and develop transformative RNA-based therapies.
- This segment is dedicated to identifying novel mechanisms of action and innovative technological advancements that improve the efficacy and safety of potential therapies. The focus is on understanding viral pathogenesis, host-virus interactions, and immune responses to better tailor therapies that can effectively combat infections.
2. Therapeutics Segment:
- The therapeutics segment is characterized by a portfolio of RNA-based therapies that target a range of viral infections, including but not limited to hepatitis B, HIV, and influenza. These therapies are in various stages of clinical development, demonstrating the companys commitment to bringing effective treatments to market for significant public health challenges.
- In addition to these viral indications, Arbutus explores potential applications of its RNA-based therapies in oncology and other viral infections, showcasing the versatility and potential of RNA technology to address multiple diseases.
- Preclinical studies are actively conducted to evaluate the safety and efficacy of these therapies, contributing to the robust pipeline of drug candidates in development.
3. Partnerships Segment:
- Arbutus Biopharma strategically engages in partnerships and collaborations with leading pharmaceutical companies, biotechnology firms, and academic institutions globally. These alliances are intended to expedite the development and commercialization of RNA-based therapies.
- The company actively licenses proprietary technologies and intellectual property rights to foster innovation and leverage external expertise, enhancing its capability to bring novel therapies to patients.
- Collaborative efforts often include sharing resources and knowledge, which can lead to synergistic advancements in RNA technology and therapeutic applications.
Products and Services
1. Lipid Nanoparticle (LNP) Technology:
- Arbutus holds a comprehensive patent portfolio related to LNP technology, which serves as a crucial delivery system for RNA-based therapies. Their proprietary LNP platform facilitates the efficient and targeted delivery of therapeutic RNA molecules to specific organs and tissues.
- This technology has gained prominence in the sector and has been employed in various approved RNA-based treatments for conditions such as cancer and rare diseases, highlighting its effectiveness in enhancing therapeutic outcomes.
2. C-Mer Side Effect Mitigation Technology:
- The C-Mer technology developed by Arbutus is designed to significantly reduce the side effects associated with RNA-based therapies. By mitigating the activation of the innate immune system, which can lead to potentially toxic responses, this proprietary technology enhances the safety profile of these therapies.
- This innovation is crucial, as reducing adverse effects can improve patient adherence and overall treatment efficacy, making it a vital component of the companys therapeutic offerings.
3. HBV RNAi Portfolio:
- The HBV RNAi portfolio encompasses a suite of RNA interference (RNAi)-based therapies specifically targeting the hepatitis B virus. These therapeutic candidates have shown promise through multiple preclinical trials, and many are currently advancing into clinical evaluation phases.
- The versatility of RNAi technology for silencing viral genes presents a novel approach to treating chronic hepatitis B, and this portfolio exemplifies Arbutuss commitment to addressing significant unmet medical needs in virology.
Overall, Arbutus Biopharma Corp operates at the cutting edge of scientific innovation, focusing on RNA-based therapeutic solutions to address infectious diseases. With a strong emphasis on R&D, a diverse pipeline of therapeutic candidates, and strategic partnerships, the company remains committed to enhancing patient outcomes through the development and commercialization of its technologies and therapies.